Some studies have shown that targeted nanomicrobubble contrast agents have good specificity, and some scholars have applied the contrast agent specifically targeting VEGFR2/KDR in clinics, and this targeted contrast agent can significantly improve the signal intensity of lesions in patients with breast and ovarian cancer, which improves the efficiency of clinical diagnosis and provides a new starting point for the clinical translation of targeted contrast agents [13–15]. Here, KDR is linked to ovarian cancer.